Abstract:Chemoresistance has been a significant problem affecting the efficacy of drugs targeting tumors for decades. MGMT, known as O-6-methylguanine-DNA methyltransferase, is a DNA repair enzyme that plays an important role in chemoresistance to alkylating agents. Hence, MGMT is considered a promising target for tumor treatment. Several methods are employed to detect MGMT, each with its own advantages and disadvantages. Some of the detection methods are; immunohistochemistry, methylation-specific PCR (MSP), pyrophosphate sequencing, MGMT activity test, and real-time quantitative PCR. Methylation of MGMT promoter is a key predictor of whether alkylating agents can effectively control glioma cells. The prognostic value of MGMT in glioma is currently being explored. The expression of MGMT gene mainly depends on epigenetic modification-methylation of CpG island of MGMT promoter. CpG island covers a length of 762 bp, with 98 CpG sites located at the 5' end of the gene, ranging from 480 to 1,480 nucleotides. The methylation sites and frequencies of CpG islands vary in MGMT-deficient tumor cell lines, xenografts of glioblastoma and in situ glioblastoma. Methylation in some regions of promoter CpG islands is particularly associated with gene expression. The change in the methylation status of the MGMT promoter after chemotherapy, radiotherapy or both is not completely understood, and results from previous studies have been controversial. Several studies have revealed that chemotherapy may enhance MGMT expression in gliomas. This could be through gene induction or selection of high MGMT-expressing cells during chemotherapy. Selective survival of glioma cells with high MGMT expression during alkylating agent therapy may change MGMT status in case of recurrence. Several strategies have been pursued to improve the anti-tumor effects of temozolomide. These include the synthesis of analogs of O-6-meG such as O-6-benzylguanine (O-6-BG) and O-6-(4-bromothenyl) guanine (O-6-BTG), RNAi, and viral proteins. This review describes the regulation of MGMT expression and its role in chemotherapy, especially in glioma. Targeting MGMT seems to be a promising approach to overcome chemoresistance. Further studies exploring new agents targeting MGMT with better curative effect and less toxicity are advocated. We anticipate that these developments will improve the current poor prognosis of glioma patients.

Promoter Hypermethylation of DNA-repaired Gene MGMT in Gliomas

Promoter Hypermethylation of DNA Repair Gene O~6- methylguanine DNA Methyltransferase in Gliomas

Incidence and prognostic value of multiple gene promoter methylations in gliomas

Application of MGMT Promoter Methylation of Cerebrospinal Fluid in Diagnosis of Glioma

Heterogeneity of O6-methylguanine-DNA methyltransferase protein expression and gene promoter methylation in glioblastoma

The Correlation between Aberrant Promoter Methylation of MGMT and Immunohistochemical Expression with Clinical Prognosis in Glioblastoma Multiforme

Identification of MGMT Promoter Methylation Sites Correlating with Gene Expression and IDH1 Mutation in Gliomas

O-6-Methylguanine-Dna Methyltransferase (Mgmt): Challenges And New Opportunities In Glioma Chemotherapy

Heterogeneity Of Mgmt Gene Promoter Methylation And Protein Expression In Serial Specimens In Newly Diagnosed Glioblastoma

The Prognostic Value of MGMT Promoter Methylation in Glioblastoma Multiforme: a Meta-Analysis

Proteomic and Metabolomic Analyses Illustrate the Mechanisms of Expression of the O6-methylguanine-DNA Methyltransferase Gene in Glioblastoma

Comprehensive Analysis of MGMT Promoter Methylation: Correlation with MGMT Expression and Clinical Response in GBM.

Direct, Real-Time PCR (methylight) Assay for Methylation of O6-methylguanine-DNA Methyltransferase Promoter in Glioma.

Implications of Advances in Studies of O6-Methylguanine-DNA- Methyltransferase for Tumor Prognosis and Treatment

MGMT gene promoter methylation in malignant melanoma patients

Promoter Methylation of Mgmt in Paired Primary and Recurrent Glioblastomas.

Discriminating MGMT Promoter Methylation Status in Patients with Glioblastoma Employing Amide Proton Transfer-Weighted MRI Metrics

Mgmt Promoter Methylation Correlates With An Overall Survival Benefit In Chinese High-Grade Glioblastoma Patients Treated With Radiotherapy And Alkylating Agent-Based Chemotherapy: A Single-Institution Study

MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response

Promoter Hypermethylation of DNA Repair Gene MGMT in Laryngeal Squamous Cell Carcinoma

Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients